Comparison of the efficacy of entecavir and lamivudine in the treatment of chronic hepatitis B:A meta-analysis

African Journal of Biotechnology

Volumn 10, Issue 41, 2011, Pages 8131-8136

  Liu, An Nuo ^a   Zhang, Li Zhou ^a   Cheng, Jun ^a   Zhang, Tian Chen ^a   Pan, Fa Ming ^a   Zhang, Zhen Hua ^a   Li, Xu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Entecavir; Lamivudine; Meta analysis; Treatment

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ARTICLE; CASE CONTROL STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEPATITIS B; HUMAN; META ANALYSIS; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 79961198228     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/ajb10.2719     Document Type: Article

References (30)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 27: 1670-1677.
2. An Y, Zhang LX, Yu JH, Zhang QG, Li QM, Wang YZ (2009). The efficacy of entecavir in patients with chronic hepatitis B treatment for 48 weeks. Chin. J. Exp. Clin. Infect Dis. (Electronic Edition). 3: 396-400. in chinese
3. Cai HD, Ma XY, Cao CM, Xu YL, Bu ZJ (2007). Comparison of antiviral effects and safety between entecavir and lamivudine in patients with chronic hepatitis B. ADRJ. 9: 7-10. in chinese
4. Chang TT, Gish RG, de Man R, Gadnno A, Sollano J, Chao YC (2006). A comparison of entecavir and lamivudine for HBeAg-Positive chronic hepatitis B. N. Engl. J. Med. 353: 1001-1010.
5. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM (2004). Four years of lamivudine treatment in Chinese patients withchronic hepatitis B. J. Gastroenterol. Hepatol. 19: 1276-1282.
6. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM (2004). Four years of Lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19: 1276-1282.
7. Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R Z (2009). Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J. Viral Hepat. 16: 784-789.
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA., 295: 65-73.
9. Chen CY, Wu QH, Liang D, Xiao XZ, Ma LY (2008). Cost-efficacy analysis of lamivudine and entecavir in patients with chronic hepatitis B. China Med. Herald. 101-102. in chinese
10. Chen Q, Qiu BD (2009). Anti-virus therapy of entecavir in the treatment of chronic hepatitis B at the initial stage. Hainan Med. J. 20: 183-184. in chinese
11. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341: 1256-1263.
12. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S (1998). Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42: 3209-3217.
13. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J (2007). Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology, 133: 1437-1444.
14. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006). Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 130: 678-686.
15. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ (1997). Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 41: 1444-1448.
16. Keeffe EB, Dieferich DT, Han SH, Jacobson IM, Martin P, Schiff ER (2006). A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An Update. Clin. Gastroenterol. Hepatol. 4: 936-962.
17. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI (1998). A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339: 61-68.
18. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z (2006). Entecavir versus lamivudine for patients with HBeAg-Negative chronic hepatitis B. N. Engl. J. Med. 353: 1011-1020.
19. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H (2004). Lamivudine for patients with chronic hepatitis B and advanced liverdisease. N. Engl. J. Med. 351: 1521-1531.
20. Lok AS, McMahon BJ (2007). American Association for the Study of Liver Diseases (AASLD) practice guidelines. Chronic Hepatitis B. Hepatol. 45: 507-539.
21. Lok AS, Mcmahon BJ (2009). Chronic hepatitis B: update 2009 Hepatology, 50: 661-662.
22. Marion PL, Salazar FH, Winters MA, Colonno RJ (2002). Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother. 46: 82-88.
23. Omata M (1998). Treatment of chronic hepatitis B infection. N. Engl. J. Med. 339: 114.
24. Ren FY, Piao DM, Piao XX (2007). A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J. Gastroenterol. 13: 4264-4267.
25. Sacks HS, Reitman D, Pagano D, Kupelnick B (1996). Meta-analysis: an update. Mt. Sinai. J. Med. 63:216-224.
26. Schiff ER (2006). Prevention of mortality from hepatitis B and hepatitis C. Lancet, 368: 896-897.
27. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J (2009). Long-term monitoring shows Hepatitis B virus resistance to entecavir in nucleoside-naïve patients in rare through 5 years of therpy. Hepatology, 49: 1503-1514.
28. Wang YP, Li M (2009). A randomized controlled clinical trial on the treatment of entecavir verse lamivudine in patients with chronic hepatitis B. Chin. J. Clin. Infect Dis. 2: 361-362. in Chinese
29. Yao GB, Chen CW, Lu WL, Ren H, Tan DM, Wang YM (2007). Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol. Int. 1: 365-372.
30. Yao GB, Chen CW, Lu WL, Ren H, Tan DM, Wang YM (2008). Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol. Int. 2: 486-493.